Results 41 to 50 of about 241,804 (118)

Bisphosphonates as Radiopharmaceuticals: Spotlight on the Development and Clinical Use of DOTAZOL in Diagnostics and Palliative Radionuclide Therapy. [PDF]

Int J Mol Sci, 2023
Souche C, Fouillet J, Rubira L, Donzé C, Deshayes E, Fersing C.   +5 more
europepmc   +1 more source

Seeing the Invisible: The Value of Bone Scan to Distinguish Chondroblastic Osteosarcoma From Prosthesis Loosening. [PDF]

Clin Nucl Med, 2022
Chuang TL, Chen YR, Wang YF.
europepmc   +1 more source

Derivation of a specification for fission-produced molybdenum-99 for the preparation of AAEC (autoclaved) MK II B 99Mo/99m Tc generators.

, 1987
Technetium-99m eluates are shown to contain significantly lower levels of radionuclidic impurities than the parent 99 Mo feed solution. It is well established that alumina absorption of 99 Mo followed by saline elution of 99m Tc leads to a considerable ...
Druce, MJ, Boyd, RE
core  

Adverse Clinical Events at the Injection Site Are Exceedingly Rare After Reported Radiopharmaceutical Extravasation in Patients Undergoing ^99mTc-MDP Whole-Body Bone Scintigraphy: A 12-Year Experience. [PDF]

J Nucl Med, 2023
Parihar AS, Schmidt LR, Crandall J, Dehdashti F, Wahl RL.   +4 more
europepmc   +1 more source

Clinical evaluation of technetium-99m-L,L-ethylenedicysteine in patients with chronic renal failure

, 1997
Technetium-99m-L,L-ethylenedicysteine (Tc-99m-L,L-EC), a new renal radiopharmaceutical, has been shown to have similar excretion characteristics but a higher plasma clearance than Tc-99m-mercaptoacetyltriglycine (Tc-99m-MAG3) in normal volunteers and ...
Verbruggen, AM., Prvulovich, EM, Bomanji, JB, Waddington, WA, Ell, PJ, Rudrasingham, P   +5 more
core  

^99mTc-methylene diphosphonate SPECT/CT imaging of gout spondylitis: a case report. [PDF]

J Int Med Res, 2022
Wang Y, Zha Y, She R, Sun G, Li S, Liu L, Roberts N, Li Y.   +7 more
europepmc   +1 more source

Radiopharmaceutical supply disruptions and the use of ^99mTc-hydroxymethylene diphosphonate as an alternative to ^99mTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement. [PDF]

J Nucl Cardiol, 2022
Miller EJ, Campisi R, Shah NR, McMahon S, Cuddy S, Gallegos-Kattan C, Maurer MS, Damy T, Slart RHJA, Bhatia K, Einstein AJ.   +10 more
europepmc   +1 more source

Recent advances in technetium-99m radiopharmaceuticals [PDF]

, 1973
From 11th international annual meeting of the German Society of Nuclear Medicine; Athens, Greece (24 Sep 1973). The development of a number of new technetium-99m-labeled radiopharmaceuticals for use in scintiscanning is described.
Richards, P., Smith, T. D.
core  

A Comparative Study of Pharmacopoeial Quality Standards and Regulations of Radiopharmaceuticals. [PDF]

Indian J Nucl Med, 2021
Thota P, Thota A, Pandey MK, Sarma P, Medhi B, Sharma RK, Prakash J, Teotia AK.   +7 more
europepmc   +1 more source

Imaging in situ breast carcinoma (with or without an invasive component) with technetium-99m pentavalent dimercaptosuccinic acid and technetium-99m 2-methoxy isobutyl isonitrile scintimammography

, 2005
Introduction The aim of the study was to retrospectively define specific features of the technetium-99m pentavalent dimercaptosuccinic acid (Tc-99m-(V)DMSA) and technetium-99m 2-methoxy isobutyl isonitrile (Tc-99m-Sestamibi [Tc-99m-MIBI]) distribution in
Valotassiou, V, Louvrou, A, Koutsikos, J, Tsiouris, S, Sotiropoulou, M, Melissinou, M, Papantoniou, V, Zerva, C, Tzannetaki, A, Mainta, E, Souvatzoglou, M, Nakopoulou, L, Pirmettis, I, Lazaris, D   +13 more
core   +1 more source